Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.61 USD
+0.14 (9.18%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.61 +0.01 (0.31%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
Iterum Therapeutics PLC [ITRM]
Reports for Purchase
Showing records 61 - 72 ( 72 total )
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem Narrowly Misses in cIAI But We See Larger Value in UTI; Moderate PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Top-line Results of SURE 2 in cUTI on Track for 1Q20; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
3Q19 Recap First Pivotal Readout in cIAI Around Year-End 2019; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
2Q Recap Major Near-Term Catalyst in Phase 3 Topline Expected 4Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
We Highlight Several Antibiotics at the ASM Microbe 2019 Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Not Just Another Antibiotic Company; Initiate Buy Ahead of Three Phase 3 Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E